ICER publishes PCSK9 assessment
The Institute for Clinical and Economic Review (ICER) published an assessment of PCSK9 inhibitors Repatha evolocumab and Praluent alirocumab that concluded the annual value-based price for each of the two drugs should be $2,177 across all hypercholesterolemia patients. The price represents about an 85% discount to the drugs' list prices. The price was slightly higher for subpopulations, including $3,100-$4,000 for familial hypercholesterolemia ( FH), $3,900-$5,200 for statin-intolerant patients and $2,976 for patients with cardiovascular disease not at LDL target on statins alone.
Amgen Inc. (NASDAQ:AMGN) priced Repatha at $14,100 annually. Praluent from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is priced at $14,600. ...